Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Breast Cancer Res Treat. 2011 Feb 25;127(1):153–162. doi: 10.1007/s10549-011-1413-6

Fig. 1.

Fig. 1

Docetaxel clearance and CYP3A4 activity, as measured by the erythromycin breath test (ERMBT) when docetaxel was administered alone or in combination with imatinib. Each circle represents an observation while lines and dashes are the mean and median values, respectively